Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Maat PharmaXPAR:MAAT +1.30%27 Days Inventory is 25.88 as of Dec. 2025, which is 40% below its 10-year median of 43.07. GuruFocus rates XPAR:MAAT with a GF Score™ of 27/100 and a GF Value™ of €10.63 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 638 Biotechnology companies, Maat Pharma ranks better than 95.61% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). Maat Pharma's Average Total Inventories for the
six
months ended in Dec. 2025 was €0.09 Mil. Maat Pharma's Cost of Goods Sold for the
six
months ended in Dec. 2025 was €0.61 Mil.
Hence, Maat Pharma's Days Inventory for the
six
months ended in Dec. 2025 was 25.88.
The historical rank and industry rank for Maat Pharma's Days Inventory or its related term are showing as below:
XPAR:MAAT'
s Days Inventory Range Over the Past 10 Years
Min: 19.29 Med: 43.07 Max: 75.48
Current: 20.6
During the past 8 years, Maat Pharma's highest Days Inventory was 75.48. The lowest was 19.29. And the median was 43.07.
XPAR:MAAT's Days Inventory is ranked better than 95.61% of 638
companies
in the Biotechnology industry
Industry Median: 183.195
vs XPAR:MAAT: 20.60
Maat Pharma's Days Inventory
declined
from Dec. 2024 (31.10) to Dec. 2025 (25.88).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Maat Pharma's Inventory Turnover for the
six
months ended in Dec. 2025 was 7.05.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Maat Pharma's Inventory-to-Revenue for the
six
months ended in Dec. 2025 was 0.04.
Maat Pharma (XPAR:MAAT) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Maat Pharma's Inventory Turnover for the
six
months ended in Dec. 2025 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Maat Pharma's Inventory to Revenue for the
six
months ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Maat Pharma Days Inventory Related Terms
Maat Pharma Days Inventory Historical Data
* Premium members only.
The historical data trend for Maat Pharma's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAR:MAAT vs VRTX, REGN, ALNY: Days Inventory Comparison
For the Biotechnology subindustry, Maat Pharma's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Maat Pharma Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Maat Pharma's Days Inventory distribution charts can be found below:
* The bar in red indicates where Maat Pharma's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Maat Pharma (XPAR:MAAT) has a Days Inventory of 25.88 as of Dec. 2025. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Maat Pharma and its competitors. This is 40% below median its historical median of 43.07. Over the past decade, Maat Pharma's Days Inventory has ranged from 19.29 to 75.48. According to the industry distribution chart, Maat Pharma ranks #28 out of 638 companies in the Biotechnology industry, placing it in the top 4.4%.
Is Maat Pharma's Days Inventory too high?
Maat Pharma's current Days Inventory of 25.88 is 40% below median its 10-year median of 43.07. Over the past 10 years, this metric has ranged from a low of 19.29 to a high of 75.48. The Biotechnology industry median Days Inventory is 183.20. Maat Pharma's value of 25.88 is 85.9% below this industry median. Based on the distribution chart, Maat Pharma ranks #28 out of 638 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Maat Pharma has a GF Score™ of 27/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Maat Pharma's Days Inventory compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Maat Pharma ranks #28 out of 638 companies for Days Inventory. This places Maat Pharma in the top 4% of its industry — outperforming the majority of peers. The industry median Days Inventory is 183.20. Maat Pharma's value of 25.88 is 85.9% below this benchmark. Historically, Maat Pharma's own Days Inventory has ranged from 19.29 to 75.48 over the past decade. While the company's 10-year median is 43.07 vs. the industry median of 183.20, Maat Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.20, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Maat Pharma's current Days Inventory of 25.88 is 85.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Maat Pharma and its competitors. For the Biotechnology industry, the median Days Inventory is 183.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Maat Pharma's current Days Inventory is 25.88, which is 40% below median its own 10-year median of 43.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maat Pharma stock overvalued right now?
Based on GuruFocus' analysis, Maat Pharma (XPAR:MAAT) is currently considered Possible Value Trap. The stock's GF Value™ is €10.63, compared to a current price of €2.73 — trading 74.4% below its estimated fair value. The current Days Inventory is 25.88, which is 40% below median its 10-year median of 43.07 and 85.9% below the Biotechnology industry median of 183.20. Maat Pharma's overall GF Score™ is 27/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Maat Pharma (XPAR:MAAT), the current Days Inventory is 25.88 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Maat Pharma (XPAR:MAAT) Overvalued in 2026?
Based on GuruFocus' analysis, Maat Pharma stock appears to be undervalued.
The current stock price of €2.73 is trading 74.4% below its estimated GF Value™ of €10.63.
GuruFocus considers Maat Pharma to be Possible Value Trap.
Key valuation signals for XPAR:MAAT:
Days Inventory: 25.88 (40% below median its 10-year median of 43.07)
GF Value™: €10.63 vs. price of €2.73 (74.4% below fair value)
Industry Position: 85.9% below the Biotechnology median (#28 of 638)
No single metric tells the full story. See the XPAR:MAAT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Maat Pharma SA is a french clinical stage biotech and a pioneer in the development of microbiome based ecosystem therapies dedicated to improving survival outcomes for patients with cancer.
27GF Score
Get the complete analysis for XPAR:MAAT
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:MAAT has been successfully added to your 
